As reported on FierceBioTech, Biohaven closed out the holiday period with disappointing news: its investigational Kv7.2/7.3 potassium‑channel modulator, BHV‑7000, did not demonstrate efficacy in a phase 2 clinical trial for major depressive disorder (MDD).
The study, designed to enroll around 300 participants, compared six weeks of daily BHV‑7000 treatment with placebo using the Montgomery-Åsberg Depression Rating Scale as the primary endpoint. The therapy showed no meaningful improvement over placebo, a result analysts at William Blair said was not entirely unexpected given longstanding challenges in MDD trial execution and rising placebo responses across the field.
Analysts also noted that earlier Kv7‑targeting agents—such as GSK’s discontinued ezogabine and Xenon Pharmaceuticals’ azetukalner—leave limited room for demonstrating strong effect sizes in future studies. Still, they described Biohaven’s outcome as disappointing, even with some exploratory signals favoring BHV‑7000 in select patient subsets.
Biohaven reported that individuals with more severe depression appeared to respond better to the therapy on multiple measures. However, those subgroup analyses involved fewer than 30 patients, limiting the ability to draw meaningful conclusions. The company characterized the findings as hypothesis‑generating rather than actionable.
Against the backdrop of broader pipeline reprioritization, Biohaven has decided not to pursue additional psychiatric trials of BHV‑7000. The organization is instead channeling resources toward programs in immunology, obesity, and epilepsy.
As a result, analysts removed BHV‑7000’s MDD indication from their valuation models. They are now looking ahead to pivotal data from the drug’s ongoing focal‑onset epilepsy study, expected in the first half of 2026, which may clarify whether the therapy’s extended‑release formulation adequately engages the central nervous system (CNS). Questions about CNS exposure have persisted, in part because the phase 1 program reported no cases of sleepiness, a common marker of CNS activity for this drug class.
Safety findings from the MDD study showed similar adverse‑event rates across treatment and placebo groups, with headache being the most commonly reported issue in both arms. Nausea occurred at low and comparable rates, and no other side effect exceeded a 5% incidence.
The setback removes a potential competitor to Xenon’s azetukalner, now in phase 3 trials for MDD, though analysts emphasized that uncertainties surrounding BHV‑7000’s CNS penetration limit any negative implications for Xenon’s program.
